Abstract
Psoriasis is one of the most common chronic skin diseases, estimated to affect 1-3% of males and females in studied populations. Once daily application of a new two-compound product incorporating both calcipotriene and betamethasone dipropionate, has been shown to provide rapid and effective treatment of psoriasis. The tool commonly used to express disease severity is the PASI (Psoriasis Area and Severity Index). Using a retrospective, pooled analysis of results from 4 large, controlled clinical trials, the efficacy of the new ointment within subgroups based on different baseline PASI scores was investigated. Parameters analysed included the percentage reduction in PASI after 4 weeks of treatment. A total of 1534 patients received the ointment once daily. Across the 4 clinical trials, about 60% of patients studied had baseline PASI scores between 0-10, 33% had scores from 10-20, 5% from 20-30 and 1% >30. The mean percentage PASI reduction for each severity category was consistent across all groups, and ranged from 67.8% to 72.4%. Thus, the two-compound product was demonstrated to be an effective therapy in patients with a wide range of disease severities. Dr Wasel has performed clinical trials for Leo Pharma Inc. Dr Wasel has also recived honoraria from Leo Pharma Inc. for speaking engagements.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
